CN102784140B - Application of indirubin in reduction of arsenic content in body blood - Google Patents

Application of indirubin in reduction of arsenic content in body blood Download PDF

Info

Publication number
CN102784140B
CN102784140B CN201110132422.0A CN201110132422A CN102784140B CN 102784140 B CN102784140 B CN 102784140B CN 201110132422 A CN201110132422 A CN 201110132422A CN 102784140 B CN102784140 B CN 102784140B
Authority
CN
China
Prior art keywords
indirubin
arsenic
blood
standard solution
arsenic content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201110132422.0A
Other languages
Chinese (zh)
Other versions
CN102784140A (en
Inventor
许羚
王鲲
何迎春
陈君超
郑青山
石劲敏
李禄金
盛玉成
吕映华
杨娟
刘红霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai University of Traditional Chinese Medicine
Original Assignee
Shanghai University of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai University of Traditional Chinese Medicine filed Critical Shanghai University of Traditional Chinese Medicine
Priority to CN201110132422.0A priority Critical patent/CN102784140B/en
Publication of CN102784140A publication Critical patent/CN102784140A/en
Application granted granted Critical
Publication of CN102784140B publication Critical patent/CN102784140B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a new application of indirubin. Indirubin is a main component contained in indigo naturalis, and has a chemical structure of a bi-indole compound. Indirubin has inhibition effect on various transplantable animal tumors, and can destroy leukemia cells; indirubin can also enhance the phagocytosis effect of mononuclear phagocyte systems of animals. According to the invention, indirubin can reduce the arsenic content in body blood. Arsenic is a toxic substance with severe harm to human body. Research shows that when compared with a blank control group, rats administrated with indirubin have obviously reduced arsenic concentration in blood.

Description

Indirubin is the purposes in arsenic content in reducing body blood
Technical field:
The invention belongs to medical technical field, be specifically related to indirubin effect in arsenic content in reducing body blood.
Background technology:
Arsenic is present in nature widely, in industrial and agricultural production application quite wide, be a kind of toxicant that body is had to serious harm.Arsenic is protoplasm poisonous substance, its with histiocyte endoenzyme be easily in sulfydryl be combined, thereby the activity of inhibitory enzyme, cause cellular metabolism obstacle, the toxicity of formation to central nervous system, cardiovascular system, gastronintestinal system, causes that oral cavity, esophagus, gastric mucosal erosion, swelling are hemorrhage, toxic hepatitis, subacute severe hepatitis, heart fat infiltration, central nervous system's anoxia, glomerular injury etc.In recent years, endemic arsenic poisoning is more serious both at home and abroad, in China's animal husbandry, be still widely used organo-arsenic as feed additive (growth promoter), cause common food (animality and vegetalitas) all can detect arsenic, especially with marine product for the highest, as the mankind of food chain terminal, unavoidably there is in vivo certain arsenic especially and accumulate.At present, about the Therapeutic Method of arseniasis, mainly contain selenium supplement treatment, with sulfydryl, drive arsenic treatment and utilize treatment by Chinese herbs etc., but up to now, without any medicine, any therapy, obtain satisfied row's arsenic curative effect.Therefore, finding effectively medicine or the therapy of row's arsenic is a urgent task.
Summary of the invention:
Indirubin is main composition contained in Indigo Naturalis, and its chemical constitution is a bisindole compound.Molecular formula is C 16h 10n 2o 2.Indirubin has inhibitory action to multiple transplanted animal tumor, can destroy leukaemia; Indirubin can also strengthen the phagocytic activity of the mononuclear phagocyte system of animal.But indirubin is only as cancer therapy drug in medical research before, and document shows that indirubin is evident in efficacy to chronic grain leukemia in the past.
In the present invention, will for indirubin, provide a new purposes, while using separately, have the effect of obvious reduction body blood arsenic content.
Accompanying drawing explanation: Fig. 1 is blank group and the average whole blood arsenic concentration-time plot of indirubin suspension oral gavage group rat (n=12)
The specific embodiment:
-materials and methods
1.1 laboratory animal
Laboratory animal adopts male Sprague-Dawley rat, and male, body weight 320g~370g, is provided by Shanghai Slac Experimental Animal Co., Ltd., and production licence number is SCXK (Shanghai) 2007-0005.
Feeding environment is regular grade experimental animal room, temperature: 22 ℃~23 ℃, and relative humidity 40%~70%, occupancy permit number is SCXK (Shanghai) 2006-0003.
1.2 medicines and reagent
(1) As standard inventory solution 1gL -1(As standard stock solution, 1gL -1): Merck company provides, lot number HC 961324;
(2) nitric acid (Nitric acid): HPLC level, Merck company, lot number K40748356004;
(3) hydrochloric acid (Hydrochloride acid): HPLC level, Merck company, lot number K39343417841;
(4) Fluohydric acid. (Hydrofluoric acid): top grade is pure, and Chemical Reagent Co., Ltd., Sinopharm Group provides, lot number 20100520;
(5) high-purity helium (99.999%): Shanghai success gas company limited provides;
(6) indirubin raw material: purity 95%, lot number MRHGG 100313, Shaanxi Sen Fu Bioisystech Co., Ltd provides;
(7) sodium carboxymethyl cellulose (Carboxymethylcellulose sodium, CMC): Chemical Reagent Co., Ltd., Sinopharm Group provides, lot number 20100520;
(8) ultra-pure water (purified water): Millipore A10 ultra-pure water instrument preparation;
1.3 reagent preparations
(1) preparation of arsenic series standard solution
ICP-AES arsenic standard solution: precision measures As standard inventory solution (1gL -1) 0.25mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 5mgL -1arsenic standard solution; Precision measures As standard inventory solution 0.05mL, adds in 50mL volumetric flask, with deionized water, is assigned to scale, obtains 1mgL -1arsenic standard solution; Precision measures 5mgL -1arsenic standard solution 5mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 0.5mgL -1arsenic standard solution; Precision measures 1mgL -1arsenic standard solution 5mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 0.1mgL -1(100 μ gL -1) arsenic standard solution.
Precision measures above-mentioned 100 μ gL -1arsenic standard solution 25mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 50 μ gL -1arsenic standard solution; Precision measures 50 μ gL -1arsenic standard solution 20mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 20 μ gL -1arsenic standard solution; Precision measures 20 μ gL -1arsenic standard solution 25mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 10 μ gL -1arsenic standard solution; Precision measures 10 μ gL -1arsenic standard solution 25mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 5 μ gL -1arsenic standard solution; Precision measures 5 μ gL -1arsenic standard solution 10mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 1 μ gL -1arsenic standard solution.
The preparation of (2) 0.5% carboxymethylcellulose sodium solutions
Accurately take the sodium carboxymethyl cellulose powder art of 5.00g, put in 800ml beaker, add 500ml distilled water, 60 ℃ of magnetic agitation 4h, are transferred in 1000ml volumetric flask, are settled to scale.4 ℃ store for future use.
(3) preparation of medicine suspension
Indirubin suspension: precision takes indirubin 52.6mg, grinds to form fine powder, slowly adds a small amount of 0.5%CMC solution, continue to be ground to evenly, be transferred in 25mL tool plug graduated cylinder, repeatedly shift and merge, add to 25mL, be mixed with the suspension that concentration is 2gL-1.Face and join existing use.
1.4 instrument
(1) U.S. Perkin Elmer OPTIMA-DV of company 5300 type inductance couplings and plasma emission spectrometer (ICP-AES);
(2) 7500Ce of U.S. Agilent company inductance coupling and plasma mass spectrograph (ICP-MS);
(3) one of German Saturious BT2202S percentage analytical balance (taking blood sample);
(4) the rich fast experiment SSW of the company limited type electric heating constant temperature tank in Shanghai;
(5) Switzerland Mettler Toledo AL204-IC precision balance (taking raw material);
(6) Switzerland Mettler Toledo XP-205DU 100,000/precision balance (taking reference substance)
1.5 instrument settings
(1) ICP-AES instrumental method arranges
Instrument working parameter: RF power 1300w, nebulizer flow 0.8Lmin -1, assisted gas flow 0.2Lmin -1, plasma gas flow rate 15Lmin -1, peristaltic pump flow velocity 15mLmin -1, the time of integration 1~20s, analytical wavelengths 118.979nm.
(2) ICP-MS instrumental method arranges
Instrument working parameter: radio-frequency power 1500w; Sampling depth 8.0mm; Carrier gas flux 0.7Lmin -1; Assisted gas flow 0.2Lmin -1; Plasma gas flow rate 15Lmin -1; Reaction gas helium; 2 ℃ of S/C temperature; Sample hoisting velocity 0.5rps; The high salt type of nebulizer: Babington; Sampling spiroid type and diameter: nickel cone, 0.8mm; Intercepting cone type and diameter: nickel cone, 0.4mm; Drainage pattern: Spectrum; Count/quality: 3; Number of repetition: 3; Detection mode: automatically; Analytical wavelengths 118.979nm.
1.6 EXPERIMENTAL DESIGN
Choose 12 rats, non-fasting, body weight is (357.8 ± 10.7) g, be divided at random 2 groups, every group before administration and after administration 0.25,0.5,0.75,1,2,3,4,6,8,10,12,24,32,48,56,72,80,96,104,120,144h rat eye socket venous plexus gather anticoagulated whole blood 0.5mL, preserve until analyze for-40 ℃.
The administration arrangement of the different groups of table 1-1
1.7 containing arsenic sample pretreatment
Precision takes rat whole blood 0.5g to be measured in brand-new gas phase head space bottle, adds 4mL nitric acid, 1mL hydrochloric acid and 0.5mL Fluohydric acid., seals.Be positioned in 50 ℃ of water-baths and be incubated overnight.Second day is uncapped sample in head space bottle is transferred in the brand-new Falcon pipe of 15mL, and repeatedly rinse merges all liq and adds water to 15g.The centrifugal 10min of 4000rpm, gets supernatant 6mL sample introduction ICP-AES or ICP-MS and analyzes.
1.8 date processing and statistics
AUC 0-t(area under 0-144h blood arsenic-time graph) adopts statistical moment to calculate.AUC between two groups 0-t, difference adopts SNK check (q check), by SAS 9.1.3, realized.
Two results
1. arsenic standard curve
ICP-AES: standard curve was former point curve, concentration is respectively 0,0.1,0.5,1,5mgL -1, regression equation is that the range of linearity is 0~5mgL -1.
ICP-MS: standard curve was former point curve, concentration is respectively 0,1,2,5,10,20,50,100 μ gL -1, regression equation is Y=7.035e-3*X-2.813e-4, the range of linearity is 0~100 μ gL -1.
2. Pharmacokinetics in Rat
Blank group rat whole blood arsenic concentration is in Table 2-1, and the whole blood arsenic concentration after gavage drug suspension is in Table 2-2, two groups of AUC 0-tbetween value and group, comparative result is in Table 2-3.Use indirubin can make the AUC of blood arsenic 0-tsignificantly decline.
Total arsenic concentration (the mgL of whole blood of the blank group of table 2-1 rat -1)
Figure GSB00000590930100051
Table 2-2 rat oral gavage indirubin (50mgkg -1) after the total arsenic concentration (mgL of whole blood -1)
Figure GSB00000590930100061
The blood arsenic AUC of the different groups of table 2-3 0-t
Figure GSB00000590930100062
Note: " * " and blank group be P < 0.05 relatively

Claims (1)

1. the application of indirubin in the medicine of the content for the preparation of heavy metal arsenic in reducing blood.
CN201110132422.0A 2011-05-20 2011-05-20 Application of indirubin in reduction of arsenic content in body blood Expired - Fee Related CN102784140B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110132422.0A CN102784140B (en) 2011-05-20 2011-05-20 Application of indirubin in reduction of arsenic content in body blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110132422.0A CN102784140B (en) 2011-05-20 2011-05-20 Application of indirubin in reduction of arsenic content in body blood

Publications (2)

Publication Number Publication Date
CN102784140A CN102784140A (en) 2012-11-21
CN102784140B true CN102784140B (en) 2014-04-09

Family

ID=47149861

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110132422.0A Expired - Fee Related CN102784140B (en) 2011-05-20 2011-05-20 Application of indirubin in reduction of arsenic content in body blood

Country Status (1)

Country Link
CN (1) CN102784140B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103735635A (en) * 2014-01-13 2014-04-23 李绍华 Medicinal composition for treating cancers and leukemia
CN104083394A (en) * 2014-07-09 2014-10-08 云健康(福建)医疗科技有限公司 Process for preparing hemostatic anti-sticking wound healing promoting material by use of sodium carboxymethylcellulose

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia;Lan Wang et al.;《PNAS》;20080325;第105卷(第12期);4826-4831 *
Lan Wang et al..Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.《PNAS》.2008,第105卷(第12期),4826-4831.
万纹.上海交大三篇文章入选08最具影响国际论文(http://www.ebiotrade.com/newsf/2009-12/2009121173643602.htm).《生物通》.2009,第1-2页. *

Also Published As

Publication number Publication date
CN102784140A (en) 2012-11-21

Similar Documents

Publication Publication Date Title
Gokduman Strategies targeting DNA topoisomerase I in cancer chemotherapy: camptothecins, nanocarriers for camptothecins, organic non-camptothecin compounds and metal complexes
CN107213466B (en) A kind of column aromatic hydrocarbons compound, preparation method, pharmaceutical composition and purposes
Lu et al. A reactive oxygen species-generating, cyclooxygenase-2 inhibiting, cancer stem cell-potent tetranuclear copper (II) cluster
EP2878401A1 (en) Noble metal nanoparticles, method for preparing the same and their application
CN107485718B (en) Combined nano preparation of camptothecin and taxus medicine and preparation thereof
CN101590057A (en) The anti-tumor compositions that contains Taxane derivative
CN102784140B (en) Application of indirubin in reduction of arsenic content in body blood
CN104478890A (en) All-trans retinoic acid-camptothecin anticancer drug conjugate as well as preparation method and application thereof
CN107569515B (en) Carbon quantum dots/cuprous oxide (CQDs/Cu)2Application of O) complex in preparation of medicine for treating cancers
CN108084177A (en) A kind of jamaicin 9- pyrazole derivatives and its preparation and application
TW201330847A (en) Composition for preventing and treating cancer and method for manufacturing the same
CN102784151B (en) Application of combination of tanshinone IIA with indirubin in reduction of arsenic content in body blood
CN109620836B (en) Compound pharmaceutical composition with breast cancer resistance, application thereof and medicine based on composition
CN102784152B (en) Application of tanshinone IIA in reduction of arsenic content in body blood
CN101234122B (en) New purpose of polylysine
CN101564392A (en) Novel application of sanguinarine
CN112691111A (en) New anti-tumor application of 3-boranophenyl-1-carbamic acid cholesterol ester and pharmaceutical preparation thereof
CN1120002C (en) Application of ammonium nilrate in pharmaceutical industry, food and health-care product
CN101269223B (en) Anthracene nucleus medicament nano-preparation, preparation method and application thereof
CN103784471A (en) Anti-tumor medicinal composition
CN101564393A (en) Novel application of nitidine
CN1718183A (en) Neo-garcinolic acid prepn. for injection use, prepn. method and use thereof
CN102526081A (en) Medicinal composition capable of inhibiting proliferation of tumor cells
CN110721319A (en) Preparation method of polyphosphate prodrug and prodrug nano-particle simultaneously bonded with camptothecin and adriamycin
CN103169715B (en) A kind of compound sulfamethoxazole injection and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140409

Termination date: 20200520